Myocardial tissue characteristics and glycaemic status
Research type
Research Study
Full title
Myocardial tissue characteristics in patients with heart failure according to glycaemic status.
IRAS ID
228222
Contact name
PS Swoboda
Contact email
Sponsor organisation
University of Leeds
Duration of Study in the UK
5 years, 0 months, 1 days
Research summary
Patients with type 2 diabetes and symptomatic heart failure have very poor prognosis. The precise mechanisms for this poor outcome are not known and specific, targeted therapeutic intervention therefore not available for this patient group.
The aims of this study are to utilise recently developed cardiac MRI (CMR) techniques to investigate the mechanisms of heart failure in patients with diabetes. Recent advances in CMR technology have reduced or abolished the requirement for breath-holding in CMR so that it is now possible to investigate patients with diabetes and symptomatic heart failure. Previously patients with severe heart failure often had difficulty with breath-holding to allow image acquisition and may have had to have shortened or incomplete scans as a result of this.
We aim to identify the extent and patterns of fibrosis and impaired myocardial blood flow (MBF) in heart failure patients and establish whether they are related to diabetes status.
We also aim to use data from this study to inform whether changes in tissue characteristics in patients with diabetes and heart failure are independently associated with adverse outcomes. To that end we plan to follow up the 200 patients in this study longer term but also to use data from this study to inform a future larger registry study. The identification of particular changes in the tissue characteristics such as increased diffuse fibrosis (scar) and decreased blood flow response to adenosine stress will help plan future studies to use these markers as surrogate endpoints and establish if they are reversible with novel pharmacological therapies.
We will also invite a subset of 50 patients who are being treated with new heart failure and diabetes medications to attend for a second scan after 3-6 months. This scan will be to establish if these drugs induce any changes in microvascular function.REC name
Yorkshire & The Humber - Leeds West Research Ethics Committee
REC reference
17/YH/0300
Date of REC Opinion
19 Oct 2017
REC opinion
Further Information Favourable Opinion